抗白细胞介素-17A在轴性脊柱关节炎中的应用现状如何？
Anti-IL17A in Axial Spondyloarthritis-Where Are We At?
作者信息
Cheung Peter P
机构信息
Division of Rheumatology, National University Hospital, Singapore, Singapore; Yong Loo Lin School of Medicine, National University, Singapore, Singapore.
出版信息
Front Med (Lausanne). 2017 Jan 18;4:1. doi: 10.3389/fmed.2017.00001. eCollection 2017.
Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically significant response. Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis. Clinical studies and current issues surrounding the use of secukinumab will be discussed.
关于白细胞介素17-白细胞介素23通路的机制及其在脊柱关节炎（SpA）中的作用的知识，对于轴性SpA患者白细胞介素17阻断疗法的发展至关重要。此前，尽管使用了非甾体抗炎药和物理治疗，但只有抗TNF药物在活动性疾病患者中被证明具有临床疗效。然而，高达50%的患者未能获得具有临床意义的反应。司库奇尤单抗是一种靶向白细胞介素17A的全人源单克隆抗体，最近已被批准用于活动性强直性脊柱炎患者。将讨论司库奇尤单抗使用的临床研究和当前问题。
Zotero 插件